Literature DB >> 11155835

Modeling age differences in cost-effectiveness analysis. A review of the literature.

L B Russell1, J E Sisk.   

Abstract

OBJECTIVES: Cost-effectiveness analysts often present cost-effectiveness results by age to help inform decisions about the use of an intervention. Yet it is not known how well studies model the risks and costs associated with age. We reviewed published studies to examine their modeling of age differences.
METHODS: MEDLINE searches identified all cost-effectiveness analyses published between 1985 and 1997 that included adults 50 years of age and older, were based on data for developed countries, and compared cost-effectiveness ratios for adults of different ages or for initiation of an intervention at different ages; 36 articles met these criteria. They were reviewed to determine the extent to which they incorporated age-specific data. Studies that justified using the same data for all ages were counted as having varied the data element by age.
RESULTS: All studies varied life expectancy by age. Most also varied the incidence/prevalence of the target condition and the case fatality rate. Only 36% varied the effectiveness rate of the intervention by age. Costs were usually assumed constant: 42% of studies varied the cost of treating adverse effects and 17% varied the cost of treating the target condition. Whether a data element was varied did not appear to be related to the pattern of cost-effectiveness ratios by age.
CONCLUSIONS: Many studies have not modeled age differences in sufficient detail to ensure that differences in cost-effectiveness ratios by age are accurate and a sound basis for decisions. As cost-effectiveness analysis becomes more widespread, analysts should strive to incorporate more complete age-specific data.

Mesh:

Year:  2000        PMID: 11155835     DOI: 10.1017/s0266462300103198

Source DB:  PubMed          Journal:  Int J Technol Assess Health Care        ISSN: 0266-4623            Impact factor:   2.188


  2 in total

1.  Effect of patient's life expectancy on the cost-effectiveness of treatment for ocular hypertension.

Authors:  Steven M Kymes; Michael R Plotzke; Michael A Kass; Michael V Boland; Mae O Gordon
Journal:  Arch Ophthalmol       Date:  2010-05

2.  Bayesian variable selection in cost-effectiveness analysis.

Authors:  Miguel A Negrín; Francisco J Vázquez-Polo; María Martel; Elías Moreno; Francisco J Girón
Journal:  Int J Environ Res Public Health       Date:  2010-04-06       Impact factor: 3.390

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.